PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 07 August 2000 (07.08.00)	
International application No. PCT/GB99/03952	**Applicant's or agent's file reference** CAH/4906WO
International filing date (day/month/year) 26 November 1999 (26.11.99)	**Priority date** (day/month/year) 26 November 1998 (26.11.98)
Applicant HILLS, Brian, Andrew et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

19 June 2000 (19.06.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Pascal Piriou

Telephone No.: (41-22) 338.83.38

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 31/66, A61P 11/06, A61K 45/06 // (A61K 31/66, 31:66, 31:00)

A1

(11) International Publication Number: WO 00/30654

(43) International Publication Date: 2 June 2000 (02.06.00)

(21) International Application Number: PCT/GB99/03952

(22) International Filing Date: 26 November 1999 (26.11.99)

(30) Priority Data:

PCT/GB98/03543	26 November 1998 (26.11.98)	GB
9912639.3	28 May 1999 (28.05.99)	GB

(71) Applicant *(for all designated States except US)*: BRITANNIA PHARMACEUTICALS LIMITED [GB/GB]; 41/51 Brighton Road, Redhill, Surrey RH1 5TS (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HILLS, Brian, Andrew [AU/AU]; 44 Bowsprit Parade, Cleveland, Queensland, NSW 4163 (AU). WOODCOCK, Derek, Alan [GB/GB]; 44 Shrublands Road, Berkhampstead, Hertfordshire HP4 3HX (GB). STANIFORTH, John, Nicholas [GB/GB]; High Trees, 170 Boomfield Road, Bath, Avon BA2 2ST (GB).

(74) Agents: HUMPHREYS, Ceris, Anne et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: ANTI-ASTHMATIC COMBINATIONS COMPRISING SURFACE ACTIVE PHOSPHOLIPIDS

(57) Abstract

A combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administered to the lungs by inhalation, for example, by a device 1.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

2/PRTS

09/856400
Rec'd PCT/PTO 2 2 MAY 2001
PCT/GB99/03952

ANTI-ASTHMATIC COMBINATIONS COMPRISING SURFACE ACTIVE PHOSPHOLIPIDS

This invention relates to pharmaceutical products for use in the treatment of asthma and to delivery devices including the products.

It has been estimated that asthma affects between 4 and 10 percent of the population, causing distress and alarm to both sufferers and bystanders. Asthma attacks appear to be precipitated in many cases by a number of factors such as exercise or pollutants in the inspired air. Other agents such as pollen and airborne particles may predispose an asthma sufferer to an attack by sensitising the airways. This has led to the belief that effective treatment should include administration of drugs which reduce the sensitivity of asthma sufferers to allergens or which neutralise the allergic reaction.

The lungs and airways of non-asthmatics may contain a natural protective barrier which prevents pollutants and other potential irritants from reaching receptors which would otherwise produce an acute attack. Studies have suggested that it is possible to simulate in the lungs of asthma sufferers the situation in normal lungs by causing surface-active phospholipids (SAPL) to bind to the tissue surface of the lungs, thereby reducing the number of receptors exposed to noxious stimuli and reducing the broncho-constrictor reflex.

SAPLs are used clinically for the treatment of respiratory distress syndrome (RDS) in neonates. In this role, it has been assumed that the SAPL functions by reducing the high surface tension forces at the air-water interface within the alveoli, thereby reducing the pressure needed to expand the lungs, see Bangham et al., Colloids &

Surfaces, 10 (1984), 337 to 341. Thus, commercially available formulations of SAPL have been designed to spread rapidly over an air-aqueous interface, thereby reducing what is otherwise a very high surface tension of water.

Limited clinical studies have been carried out to determine the effect of commercial SAPLs marketed for treatment of RDS in neonates on asthmatic subjects, - see Kurashima *et al* Jap. J. Allergol 1991; 40, 160. This paper reported some amelioration of bronchoconstriction in asthmatic adults using an SAPL obtained by extraction from bovine lungs. In another study on children, also using an SAPL obtained from bovine lungs, no significant changes in lung function or histamine response were found, - see Oetomo et al - American Journal of Respiratory and Critical Care Medicine 153; 1996, page 1148.

EP 0 528 034A describes the use of pulmonary surface active material as an ingredient of an antiasthmatic, which is in the form of a liquid or suspension for injection or spraying into the patient's air way.

The invention provides a therapeutic combination product for use in the prevention and/or treatment of asthma comprising

(a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature; and

b) an antiasthma drug;

wherein ingredients (a) and (b) are provided in a form for administration together or separately.

It is believed that the finely divided powder of ingredient (a), which preferably comprises at least first and second components, has two important effects:-

First, the medicament (a) has surfactant properties, which enable it to spread rapidly over the surfaces of the lungs and air passages. It is an important feature of the present invention that the medicament (a) is in the form of a powder, that is, it is in solid form. The "dry" surfactant has a high surface activity. It is believed that, on contact of a first component of the medicament (a) with the mucous within the lungs, the presence of a second component results in a lowering of the melting point of the first component, promoting rapid spreading of the first component over the liquid-air interface as a thin film at body temperature. For example, the normal melting temperature of dipalmitoyl phosphatidyl choline, which is a preferred first component, is about 40°C, that is, above the normal body temperature. When used in combination with a suitable second component, such as a phosphatidyl glycerol, however, the melting point of the dipalmitoyl phosphatidyl choline can in effect be reduced to below the normal body temperature.

Second, once the surface active medicament is *in situ* over the surfaces of the lungs and air passages, a component of the composition is thought to migrate across the mucous layer enabling a thin hydrophobic lining or coating to be adsorbed onto the tissue surface. Thus, over and above the surface tension reducing properties mentioned above, the medicament of the invention is believed to provide a protective effect by virtue of the adsorbed layer. In binding to the epithelium, the phospholipid may mask the irritant receptors which elicit the bronchorestrictor reflex, that is, which cause narrowing of the bronchi.

The medicament (a) is in finely divided solid form. It is believed that, as a consequence of the high surface activity of medicament (a) in that form there results a

significant drop in surface tension on contact with the aqueous mucous layer of the lung, giving enhanced effectiveness of ingredient (a) and permitting improved access to the lung surfaces for the antiasthma drug(s) to be administered. Thus, the use of the medicament (a) in combination with an antiasthma drug is believed to enhance the effectiveness of the antiasthma drug.

Moreover, as mentioned above, the binding of the phospholipid component to the lung surface is believed to reduce bronchorestriction as a consequence of a reduction in receptor-mediated activity attributable to the masking of irritant receptors. That reduced bronchorestriction acts cumulatively with the anti-bronchorestrictive activity of the antiasthma drug. Thus, in some circumstances it may be possible for dosages of an antiasthma drug to be administered to a given patient to be reduced, as a consequence of the synergistic effect of medicament (a) in enhancing the effectiveness of the antiasthma drug as well as the additional anti-bronchorestrictive activity of medicament (a) itself.

"Finely divided" as used herein means that the material has a particle size distribution which is such that at least a major proportion by weight of the particles are small enough to enter into a patient's airways and, preferably, deep into the lungs when inhaled. In practice, the first and second components preferably each have a particle size distribution which is such that not less than 90%, by weight, of the particles of those components in combination, and more preferably of each of the first and second components, have a particle size of not greater than 10μm, and especially of not greater than 5μm. Advantageously, the median particle size of the combined first and second components, and more preferably of each of the first and

second components is not more than 10μm, and preferably not more than 5μm. The median particle size may be less than 3μm, for example, about 1.2μm. It may be desirable in some circumstances for the particles to have a median particle size of at least 0.5μm. The size of the particles may be calculated by laser diffraction, or by any other method by which the aerodynamic diameter of particles can be determined. "Median particle size" as used herein means mass median aerodynamic diameter ("MMAD"). The MMAD may be determined using any suitable method, for example, using a Multi-Stage Liquid Impinger in accordance with the method described in European Pharmacopoeia (supplement 1999) 2.9.18 (Aerodynamic assessment of fine particles). Alternatively, the size distribution of the particles may be characterised by their volume mean diameter (VMD). Advantageously, the VMD is not more than 10μm, for example not more than 5μm, and preferably less than 3μm. Finely divided dry powders of this kind (which may be described as fumed powders) can be adsorbed onto the surfaces of lung tissue and are believed, in use, to become bound to the epithelium.

A finely divided solid mixture of said first and second components of the medicament (a) may be obtained by size reduction of larger particles by any suitable size reduction method, preferably before mixing. Preferably, the first component of the medicament (a) comprises one or more compounds selected from the group consisting of diacyl phosphatidyl cholines. Examples of suitable diacyl phosphatidyl cholines (DAPCs), are dioleyl phosphatidyl choline (DOPC); distearyl phosphatidyl choline (DSPC) and dipalmitoyl phosphatidyl choline (DPPC). Each of those compounds appears to be capable of forming a thin film or coating on surfaces of the lungs. Most preferably, the first component is DPPC.

The second component may comprise one or more compounds selected from the group consisting of phosphatidyl glycerols (PG); phosphatidyl ethanolamines (PE); phosphatidyl serines (PS); phosphatidyl inositols (PI) and chlorestyl palmitate (CP).

Phosphatidyl glycerol (PG) is believed to be capable of binding to lung tissue and possibly enhancing the binding of the first component and is, therefore, a preferred second component. PG is also a preferred second component because of its ability to form with the first component a very finely-divided, dry powder dispersion in air.

The medicament advantageously comprises a diacyl phosphatidyl choline and a phosphatidyl glycerol. The phosphatidyl glycerol is advantageously a diacyl phosphatidyl glycerol. The acyl groups of the phosphatidyl glycerol, which may be the same or different, are advantageously each fatty acid acyl groups which may have from 14 to 22 carbon atoms. In practice, the phosphatidyl glycerol component may be a mixture of phosphatidyl glycerols containing different acyl groups. The phosphatidyl glycerol is expediently obtained by synthesis from purified lecithin, and the composition of the acyl substituents is then dependent on the source of the lecithin used as the raw material. It is preferred for at least a proportion of the fatty acid acyl groups of the phosphatidyl glycerol to be unsaturated fatty acid residues, for example, mono- or di- unsaturated C18 or C20 fatty acid residues. Preferred acyl substituents in the phosphatidyl glycerol component are palmitoleoyl, oleoyl, linoleoyl, linolenoyl and arachidonoyl. The medicament preferably comprises dipalmitoyl phosphatidyl choline and phosphatidyl glycerol, with the phosphatidyl moiety of the phosphatidyl glycerol

advantageously being obtainable from the phosphatidyl moiety of egg lecithin.

The first and second components of the medicament (a) may be present in a weight ratio of from 1:9 to 9:1. Advantageously, the proportion by weight of the first component exceeds that of the second component. Preferably, said first component and said second component are present in a weight ratio of from 6:4 to 8:2. At a weight ratio of about 7:3, the mixture spreads rapidly at a temperature of 35°C or above.

DPPC can be prepared synthetically by acylation of glycerylphosphorylcholine using the method of Baer & Bachrea - Can. J. Of Biochem. Physiol 1959, 37, page 953 and is available commercially from Sigma (London) Ltd. The PG may be prepared from egg phosphatidylcholine by the methods of Comfurions *et al*, Biochem. Biophys Acta 1977, 488, pages 36 to 42; and Dawson, Biochem J. 1967, 102, pages 205 to 210. When co-precipitated with DPPC from a common solvent such as chloroform, PG forms with DPPC a fine powder which spreads rapidly over the surfaces of the airways and lungs. The most preferred composition of the invention contains DPPC and a phosphatidyl glycerol derived from egg phosphatidyl choline and having a mixture of C16, C18 (saturated and unsaturated) and C20 (unsaturated) acyl groups. One form of that composition is obtainable from Britannia Pharmaceuticals Ltd., 41-51 Brighton Road, Redhill, Surrey, under the trade mark "ALEC". For use in the device of the present invention, however, it is preferred for the particle size of the mixture to be less than that of "ALEC" in the form in which it is currently obtainable commercially. To obtain a mixture in which the particle size is suitable for use in the device of the invention, the phospholipid components may be dissolved in a suitable solvent, for

example ethanol, the solution filtered and vacuum-dried, and the solid product size-reduced to obtain particles of the desired size. During size-reduction, care should be taken to protect the mixture from moisture, oxygen, direct heat, electrostatic charge and microbial contamination.

"Antiasthma drug" is used herein to include any drug which has biological activity against asthma. It will be appreciated that, as used herein, "antiasthma drug" is to be understood as not including the compositions of the medicament of ingredient (a). The antiasthma drug may comprise one or more respiratory drugs including but not limited to drugs selected from the group consisting of $ß_2$-agonists, steroids, cromones, antimuscarinic drugs and leukotriene receptor antagonists. The combination product may comprise one or more said antiasthma drugs in an amount of up to 10 parts, especially up to one part by weight per hundred parts by weight of said first and second components, in combination, of the said medicament (a). It will be appreciated that the respiratory drug or drugs should be present in such an amount that each dose delivered by the device contains an effective amount of the drug or drugs.

The combination product may comprise a $ß_2$-agonist which may be terbutaline, a salt of terbutaline, for example terbutaline sulphate, or a combination thereof or may be salbutamol, a salt of salbutamol or a combination thereof. Salbutamol and its salts are widely used in the treatment of respiratory disease. The active particles may be particles of salbutamol sulphate. Long-acting $ß_2$ adrenoceptor agonists may be present, for example, formoterol, salmeterol, and salts thereof.

The combination product may comprise an antimuscarinic drug, for example ipatropium bromide.

The combination product may comprise a steroid, which may be, for example, beclomethasone dipropionate, budesonide, triamcinolone acetonide or may be fluticasone. The medicament may comprise other prophylactic drugs, including cromones, for example, sodium cromoglycate or nedocromil. The medicament may include a leukotriene receptor antagonist.

Advantageously, at least ingredient (a) is arranged to be delivered to a patent in the form of at least one individual inhalable dose, the or each individual dose comprising said first and second components of ingredient (a) in a combined amount of at least 10mg. Whereas phospholipids have been disclosed previously as adjuvants in certain forms of delivery device, the amounts of phospholipid administered in a dose by those previously disclosed devices have been much smaller than those envisaged according to the present invention. In fact, it is preferred in accordance with the present invention for each individual dose to comprise at least 25mg, and more especially at least 40mg of said first and second components. The first and second components are substantially non-toxic, and the upper limit of the dosage of ingredient (a) may therefore in general be selected having regard to convenience taking into account matters such as, for example, the comfort of the patient and/or design parameters of the device. In general, however, the device will be such that it can deliver doses of up to 1000mg, advantageously up to 500mg, preferably up to 200mg, and especially up to 100mg. Preferably, at least ingredient (a) is arranged for sequential delivery of a multiplicity of inhalable doses.

The products of the invention have the further advantage that the first and second components of the

medicament (a) may be of synthetic origin. It has been found undesirable to expose asthmatic patients to proteins of animal origin, because such proteins can have a sensitising effect on such patients, and thus the use of synthetic material has considerable advantages over the use of surfactants of animal origin that may contain animal protein.

Because it is desirable in the present invention to achieve a relatively long term adsorption of the medicament (a) on the lung surface, it is highly desirable that the medicament (or any active components) should not break down in the environment of the lungs. One of the factors which will reduce the life of a lining or coating will be the presence of enzymes, such as phospholipase A, capable of digesting DPPC and/or PG. Such enzymes only attack the laevorotatory (L) form, which constitutes the naturally occurring form. Therefore, the medicament should preferably contain the dextrorotatory (D) form or at least comprise a racemic mixture, which is obtained by synthetic routes. Suitable dispersion devices may employ a propellant such as a halocarbon to form the gas stream and may include a tapered discharge nozzle baffle or a venturi to accelerate particles through a discharge nozzle, and to remove oversized particles. Suitable halocarbons include hydrofluorocarbons, hydrofluorochlorocarbons and fluorochlorocarbons having a low boiling point, such as those marketed under the trade mark "Freon". The medicament may be packaged with a propellant in a pressurised aerosol container within the inhaler. Other inhalers have an impeller which mixes the powder into an air stream and delivers the powder-laden air into the patient's airways - see, e.g. US 5,577,497.

A preferred method and apparatus for administering the medicament (a) involves dispersing the powdered medicament in a propellant gas stream. For example, a pressurised canister of a liquefied gas may be connected to a vial containing the medicament. By releasing controlled amounts of gas from the canister into the vial, increments of the medicament are ejected from the vial as a cloud of powder and may be inhaled by the user. Where compatible with the characteristics of the antiasthma drug to be co-administered, that drug may be introduced into the gas stream, so that it is administered in admixture with the medicament (a). It is envisaged that, in use, one or two inhalable doses of the medicament (a), each dose containing 50mg, may be administered up to three times daily.

Where the antiasthma drug is to be administered separately and sequentially with the medicament (a) administration of the antiasthma drug may occur as and when required by the patient and the timing of administration may thus be independent of the timing of administration of the medicament (a).

The present invention provides a delivery device for administering to a patient by inhalation a medicament for the prevention or treatment of asthma, the delivery device containing a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL including a component which enhances the spreading of the medicament and the delivery device being capable of delivering of at least one individual dose in an amount of at least 10mg.

The invention also provides a delivery device for administering to a patient by inhalation a medicament for the prevention or treatment of asthma, the delivery device containing a medicament, the medicament being in finely

divided powder form and comprising a first component consisting of one or more phosphatidyl cholines and a second component consisting of one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate, the delivery device being arranged for delivery of at least one individual inhalable dose, the or each individual dose comprising said first phospholipid component and said second component in a combined amount of at least 10mg.

Furthermore, the invention provides use of (a) a surface active phospholipid (SAPL) composition in finely divided form conjointly with (b) an antiasthma drug in the manufacture of a medicament for the control of asthma.

One form of dispenser according to the invention will now be described in detail, by way of illustration, with reference to the accompanying drawings, in which:

Fig. 1 is a side elevation of a delivery device;
Fig. 2 is a similar view, but shows its interior; and
Fig. 3 is a schematic view of another embodiment of delivery device in accordance with the invention.

In the drawings, a casing 1 is formed from two plastic mouldings 2 and 3 which snap together to form a container for a pressurised canister 4 and a vial 5. Canister 4 contains a low boiling liquid, preferably a hydrofluorocarbon such as HFA-134a or HFC-227, under sufficient pressure to maintain the propellant liquid at normal room temperature. Vial 5 contains the powdered medicament (a), such as "ALEC". Canister 4 has a release valve 6 which is received in a recess 7 so that finger pressure on the inverted end 8 of the canister will cause

propellant to be released into a tube 9. Tube 9 is typically a hard plastics, e.g. pvc or polypropylene, tube of about 2-3mm outside diameter and about 0.5 to 2mm inside diameter. Tube 9 connects valve 6 with a fitting 10 and thence to a tube or needle 11 which extends into the vial 5. Vial 5 may be closed with a rubber seal which is penetrated by the tube or needle 11 and self-seals around the tube or needle. A second needle or tube 12 extends part way into the vial through the rubber seal in the neck of the vial and connects with a fitting 13. Fitting 13 discharges into a mouthpiece 14 which is a comfortable shape for the user to place in the mouth. When the patient is in need of medication, he places the mouthpiece 14 into his mouth and breaths and simultaneously depresses the canister 4. This causes a cloud of medicament to be dispensed into the patient's airways. Fittings 10 and 13 may be valves. Valves 10 may be set to permit measured quantities of propellant to enter the vial. Similarly, valve 13 may be set to release when the pressure in the vial reaches a predetermined level. It will be appreciated that the dispenser can be used one-handed in an analogous manner to a conventional nebulizer.

The antiasthma drug may be administered separately from a separate device either immediately before or after administration of the medicament (a), or separately as required by the patient. The antiasthma drug may be dispensed from any suitable form of inhaler device, such as a dry powder inhaler or pressurised metered dose inhaler. Such devices containing antiasthma drugs are well known and widely available commercially, and do not require further explanation.

Instead, in addition to the powdered phospholipid composition, the vial 5 may incorporate other known

pulmonary or respiratory medicaments such as salbutamol, Beclomethasone, corticosteroids, or other asthma drugs. It is, however, preferred to package the conventional asthma drug in the propellant canister or in a capsule interposed between the propellant container and the vial containing the phospholipid composition. In this way, the lungs and airways receive a cloud of phospholipid composition and an aerosol of the conventional drug sequentially or simultaneously. This combined therapy gives both quick relief and lasting protection as the film of phospholipid composition spreads over the lung tissue. Instead of packaging the phospholipid composition in a multi-use vial, it may be contained in a capsule, which may be a single use quantity, between the outlet from the propellant canister and the mouthpiece.

Another form of delivery device is illustrated in Fig. 3.

Conceptually, the device 101 shown in figure 3 provides a receptacle 102 having a volume of several litres which is filled with aerosolubilized solid SAPL composition, optionally also including an antiasthma drug, and is then inhaled by a patient via a breathing tube 120 connected to a pipe 104 leading from the receptacle. Receptacle 102 is first evacuated using vacuum pump 115. A quantity of the solid, powdered SAPL composition is contained within a mesh type holder 105 within a tube 106, and air is then introduced through the tube 106 to cause the SAPL powder to form an aerosolubilized cloud within the receptacle 102. When receptacle 102 reaches approximately atmospheric pressure, breathing tube 120 is opened to permit the patient to inhale the SAPL composition.

The device 101 comprises a stainless steel receptacle 102 of volume approximately 4 litres which has an aperture

103 at its top extremity to which a vertically extending pipe 104 is connected. Pipe 104 is connected to a transverse pipe 109 and also a breathing tube 120 which extends through a screen 121, so that the apparatus is not visible to the patient. Breathing tube 120 may be fitted with a plug at its distant end, the plug being removable before use. A mesh holder 105 is mounted on the top of the receptacle 102 as part of a connection between an air line 106 and the receptacle. The mesh holder can be disassembled to introduce a quantity of powdered medicament into the delivery device. One end of the air line 106 is connected, via the mesh holder, to the receptacle 102 via a port 103. The other end of the air line 106 is connected, via control device 107, to a regulated source 108 of compressed propellant, e.g. air. If desired, the source of compressed propellant can also contain a biologically active component for the treatment of asthma. The pipe 104 extends upwardly from receptacle to meet a horizontally extending pipe 109, from one end of which there extends pipe 110 to atmosphere. A valve 111, openable by means of a handle 112, is provided in the horizontally extending pipe 109, closing off the pipe 110 from the receptacle 102 except when valve 111 is open.

At the other end of the horizontal pipe 109 there is provided a pressure gauge 113. At that end, the horizontal pipe 109 is connected to an air line 114, which extends, *via* the control device 107, to a vacuum pump 115, which is controllable independently of the control device 107. A valve 116, operable by a handle 117, is provided for the purpose of opening or closing the pipe between the receptacle 102 and the air line 114.

A safety pressure relief valve 118 is incorporated in the apparatus and is preferably arranged to open at 0.034 bar above atmospheric pressure.

In use, micronised SAPL composition (optionally together with an antiasthma drug) may be introduced into the mesh holder device 105, which is then inserted into the port 103 leading into the receptacle 102. On insertion of the mesh holder device, the receptacle is sealed, the valves 111 and 116 both being closed. The pressure inside the receptacle 102 is then reduced by means of opening valve 116 and pumping air out of the receptacle 102 through air line 114.

Control unit 107 may include a needle valve (which may be adjustable) to control the rate at which air is evacuated from the receptacle 102. If pressure falls too rapidly in the receptacle, it may cause the powdered medicament in the mesh holder device to be sucked prematurely into the receptacle. Thereafter, the valve 116 is closed. Whilst the receptacle 102 remains sealed at reduced internal pressure, the regulated compressed air source 108 is actuated temporarily to inject air into the receptacle 102 through the mesh holder device 105. As a consequence, the powder in the mesh holder device 105 becomes aerosolised and enters the receptacle 102. The pressure may be monitored using the pressure gauge 113 and should at this stage be at or slightly below atmospheric pressure.

The plug is then removed from the mouthpiece of the breathing tube and the patient can then inhale the contents of the receptacle by sucking on the mouthpiece end of the breathing tube.

After the inhalation step, the valve 111 may be closed, and the cycle recommenced.

If desired, the quantity of the powder successfully aerosolised may be determined by weighing the mesh and powder before use (the weight of the mesh previously having

been determined) and weighing the mesh with any residual powder after use of the device.

As indicated above, an antiasthma drug may be present in the source of compressed propellant, or be placed in the mesh holder device with the SAPL.

If preferred, or if necessitated by the nature of the antiasthma drug to be administered in a combination treatment with the surface active phospholipid composition, the antiasthma drug may be administered separately from another device, for example, a dry powder inhaler or pressurised metered dose inhaler of known kind widely available for the administration of antiasthma drugs.

Determination of fine particle fraction of phospholipid composition

As already mentioned, finely divided ALEC for use in the products of the invention may be obtained by dissolving, filtering and vacuum-drying the components and size-reducing the solid product so obtained. The delivery of the size-reduced material was monitored using a Multi-Stage Impinger (MLSI) in accordance with the method described in European Pharmacopoeia (supplement 1999), 2.9.18 (Aerodynamic assessment of fine particles). Vials of the material were loaded on the 5-stage MLSI and delivery of the material tested under a number of operating conditions. Each volume of air drawn of 4l is considered equivalent to one patient inhalation. The results, in Table 1, showed that a relatively large respirable fraction was generated. The respirable (or fine particle) fraction represents particles which reach stages 3, 4 and 5 of the MSLI, indicating a particle size of less than about 5.3μm. Such particles are considered to be of a size such that they would enter deep into the lung of a typical patient.

Table 1.

Flow Rate Through MSLI (L/min)	Volume of Air Drawn (Litres)	Total Mass of Phospho-lipid Loaded (mg)	Mass Delivered into Device (mg) (% of mass loaded)	Mass of Phospho lipid MSLI (mg)	Fine Particle Fraction (mg)	Fine Particle Fraction (% ex-device)
100	4L	179.1	150.3 (84%)	55.1	46.5	84.5
100	2 x 4L	169.2	132.5 (78%)	60.0	45.1	75.1
100	3 x 4L	162.0	133.1 (82%)	66.0	55.7	84.4
100	3L	136.1	119.8 (88%)	58.6	45.1	76.9
100	4L	129.7	107.9 (83%)	53.0	44.7	84.3
100	2 x 4L	113.5	94.0 (83%)	46.1	37.6	81.7
100	4 x 4L	387.6	340.4 (88%)	117.5	86.5	73.6

Determination of surface activity of phospholipid compositions

A 2cm x 2cm platinized grey dipping plate is heated to cherry red using the flame from a Bunsen burner or similar torch. The plate is suspended from an electronic balance capable of weighing up to 500mg.

To calibrate the apparatus, a small teflon dish is filled with distilled water at approximately 20°C (room temperature) and placed on a laboratory jack just beneath the dipping plate. The dish is then raised so that the dipping plate just breaks the surface of the water, evenly along the bottom edge. The meniscus drawn up the dipping place is used to set the display of the pen recorder of the electronic balance to read about $73mNm^{-1}$ (the air/water surface tension of water at 20°C). The Teflon dish is lowered, emptied, cleaned, dried and then filled with reagent grade methanol. The dipping plate is cleaned as described above. The dish is then raised so that the dipping plate just breaks the surface of the methanol, evenly along the bottom edge. The meniscus drawn up the

dipping plate will cause the pen recorder to read about $22mNm^{-1}$ (the air/methanol surface tension of methanol at 20°C[1]). The Teflon dish is lowered and the dipping plate is cleaned as described above. A zero-reading should be obtained for the cleaned plate alone (i.e. suspended in air).

To obtain a quantitative measure of the surface activity of a material, the Teflon dish is warmed to about 37°C, filled with water at not more than 37°C and placed on a laboratory jack just beneath the cleaned plate. The dish is then raised so that the dipping plate just breaks the surface of the water, evenly along the bottom edge. The meniscus drawn up the dipping plate will give a reading of about $70mNm^{-1}$ (the approximate air/water surface tension of warm water). The material is applied onto the surface of the water using a small spatula. The amount applied should be sufficient to ensure that a complete monolayer has been formed on the surface of the water, such that an excess (as small free-floating particles) can be observed. The surface tension should fall instantly, that fall being recorded by the pen recorder. Equilibrium surface tension readings are taken from the pen recorder after about 1 minute. The temperature of the water in the Teflon dish should be not less than 35° C immediately after the reading is taken.

The term "high surface activity" as used herein with reference to any composition for use in accordance with the invention means that the equilibrium surface tension, as measured in the above method, is at least 10% lower than the surface tension before the composition is applied to the water surface. In practice, the reduction in surface tension obtainable using certain phospholipid compositions such as those mentioned above in illustration of medicament (a) may exceed 50%.

A component included in admixture with another material is to be understood as enhancing the spreading of the other material if, in carrying out the above method for determination of surface activity using the mixture and, separately, using the other material alone, the time taken for the equilibrium surface tension to be reached is shorter for the mixture, as compared to the material alone.

The above method describes determination of surface activity at 37°C. It will be appreciated that, where reference is made herein to enhancing spreading at about normal mammalian body temperature, the method should be carried out at about the normal body temperature of the relevant mammal, where that is not about 37°C.

The following Example illustrates the binding of a preferred phospholipid to the epithelium:

Example

Reagents

L-α-Phosphatidylcholine, 1,2-di[1-^{14}C]palmitoyl in Toluene:Ethanol (1:1 v/v), 114mCi/mmol, 50μCi in 2mL (CFA604 B36, Amersham)

L-α-Phosphatidylcholine, dipalmitoyl (C16:0) (P-6267, Sigma)

DL-α-Phosphatidyl-DL-glycerol, dipalmitoyl (C16:0) (P-5650, Sigma)

Egg Phosphatidylglycerol (Batch 24756, Macfarlan Smith, Ltd.)

Sodium Chloride, 0.9%, B.P. (Baxter Healthcare)

Calcium Chloride (C-4901, Sigma)

Toluene (T-4428, Sigma)

Ethanol, AnalaR (10107.7Y, BDH)

NCS-II Tissue Solubilizer, 0.5N Solution (NNCS-502), Amersham)

OCS Organic Counting Scintillant (NOCS104, Amersham)

In preparation for the dispersions in which the epithelium would be incubated, stock solutions of the phospholipid components were prepared on the first day of Run 1. These solutions were as follows:

L-α-DPPC, 2.4mg. mL^{-1} in toluene:ethanol, 1:1

DL-α-DPPG, 3.0mg. mL^{-1} in toluene:ethanol, 1:1

Egg PG, 3.0mg. mL^{-1} in toluene:ethanol, 1:1

All of the above solutions were stored at 4°C in glass vials, the threads of which were sealed with teflon tape to minimise evaporation of the solvent. Each glass vial was then placed inside a second, tightly capped glass vial. These solutions were used for each of the five runs in the trial. A solution of 200mg. L^{-1} $CaCl^2$ in 0.9% saline was also prepared on the first day of Run 2 and was used in each of Runs 2 to 5.

Equipment

Special Ultrasonic Cleaner, Model G112 SP1G (Laboratory Supplies Co. Inc., Hicksville, N.Y., U.S.A.)
VF2 Vortex (IKA-Labortechnik)
Shaking Water Bath, Model TSB2-201-A (Thermoline Scientific Equipment, Smithfield, Australia)
Contherm Series Five, Fan Forced Oven (Contherm Scientific Ltd. Lower Hutt, N.Z.) TRI-CARB 2700TR Liquid Scintillation Analyser (Packard Instrument Co., Meriden, CT, U.S.A.)
Ultrasonic Cleaner, Model FXPI2 (Unisonics Pty. Ltd. Sydney, Australia)

Bronchial Epithelium

To provide a source of bronchial epithelium, porcine lungs were obtained from an abattoir within 24h of death. The

lungs had been stored at 4°C since the time of death. The secondary bronchus was dissected from the right and/or left lungs. The exterior surface of the bronchus was trimmed of all lung tissue, and the bronchus was further cut into sections having a known surface area of bronchial epithelium (approximately 0.5cm x 0.5cm), leaving the epithelium and cartilage intact. The surface of the epithelium was rinsed with 0.9% saline to remove any mucus.

Where necessary sections of bronchial epithelium were stored in 0.9% saline at -20°C for 3 to 7 days until required for use. The sections were thawed before use on the first day of each run.

For bronchial epithelium, a total of five runs were completed. Each run consisted of three groups, as follows:

1. DPPC only
2. DPPC + DPPG
3. DPPC+eggPG

Four dispersions were prepared on the first day of each run. All groups received both 20.5μL (3.3μg) of ^{14}C-L-α-DPPC and 5.5μL (13.2μg) of unlabelled L-α-DPPC from the stock solutions. In addition, Group 2 received 5.5μL (16.5μg) DL-α-DPPG, while the same quantity of egg PG was added to Group 3. In Groups 2 and 3, the ratio of total DPPC to PG was 1:1. The phospholipid component was mixed with 6.6ml of 0.9% saline for Groups 1, 2, and 3. All of the above listed volumes were used when there were two sections of epithelium in each treatment group. When the number of sections was increased, the volumes of all components were increased

accordingly, keeping all quantities in the same proportions as above. Table 2 summarises the additives to the incubation mixtures.

Table 2. Components of Incubation Dispersions

Group	Saline	^{14}C-L-α-DPPC	L-α-DPPC	DL-α-DPPC	Egg PG
1	X	X	X		
2	X	X	X	X	
3	X	X	X		X

To solubilise the phospholipid components in the aqueous medium, each of the four incubation dispersions was sonicated for 45min, then vortexed to mix for 1min.

From each dispersion, two lots of 2.8mL were transferred to two glass vials. A single section of epithelium was incubated in each of these dispersions, so that there were four groups of two sections of bronchial epithelium in each group. Bronchial epithelium was taken from a single pig on any given day of incubation. Incubation was at 37°C for 24h in a shaking water bath.

Aliquots of the Group 1 dispersion were transferred to glass scintillation vials and incubated at 37°C in an oven for the 24h. These aliquots were used as the standards for the calibration curve. Matching aliquots from the other group dispersions were also taken, and the ß-counts from these were compared with those from the group 1 dispersion as a check that all dispersions contained the same quantity of DPPC.

On the second day of each run, the sections of epithelium were removed from the incubation dispersions and were each rinsed 20 times with 0.9% saline, warmed to 37°C

in a water bath, to remove any loosely adhering phospholipid. Care was taken not to mechanically disturb the mucosal surface of epithelium. Each section of bronchial epithelium was then removed from the attached cartilage. The sections of epithelium were further cut into smaller pieces to aid the digestion of the tissue by the solubilising agent which was added in a volume of 1 .5mL to the epithelium in scintillation vials. The same volume of solubiliser was added to each of the standard aliquots and to a blank. All vials were gently shaken to mix the contents and were warmed to 55°C in a fan-forced convection oven overnight (18-20h).

On the third day of each run, 10mL of organic counting scintillant were added to each scintillation vial, and these were vortexed to mix for 30s.

The ß-counts of each sample and standard were measured using a liquid scintillation analyser. A second count was conducted within 7h of the first count. If the two counts were similar, only the first count was used to construct the line of calibration and to quantify the samples.

From the line of calibration, the mass of ^{14}C-DPPC adsorbed to each section of epithelium was calculated. To calculate the mass of total DPPC adsorbed to each section, the mass of ^{14}C-DPPC was multiplied by 5 since the quantity of ^{14}C-DPPC in each of the dispersions was 1/5 of the total amount of DPPC. The result is expressed in Table 2 as the total amount of DPPC adsorbed per cm^2 of epithelium.

The results in Table 3 show that increased binding of DPPC to bronchial epithelium is observed in the presence of DPPG, but that the extent of binding is improved still further where Egg PG is used instead of DPPG.

While the present invention has been described with particular reference to the treatment of human patients for

asthma, it is possible that the invention may also be applicable to the treatment of other pulmonary diseases or conditions such as rhinnitis.

The combination product of the present invention may also be employed in the treatment of pulmonary conditions in other mammals. An example is reactive airway disease in horses.

Table 3.

Total DPPC Adsorbed to Bronchial Epithelium ($\mu g/cm^2$)

	DPPC	DPPC:DPPG,1:1	DPPC:Egg PG,1:1
	0.341	0.501	0.878
	0.299	0.321	0.743
	0.219	0.214	0.472
	0.116	0.263	0.731
	0.276	0.378	0.705
	0.280	0.494	0.529
	0.528	0.355	0.836
	0.192	0.419	0.792
	0.340	0.294	0.986
	0.321	0.362	0.791
n	10	10	10
Mean	0.291	0.360	0.746
SD	0.110	0.093	0.153

Claims

1. A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug, wherein ingredients (a) and (b) are provided in a form for administration together or separately.

2. A combination product as claimed in claim 1, in which the ingredient(a) consists of a first component comprising one or more phosphatidyl cholines and a second component comprising one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate.

3. A combination product as claimed in claim 2, in which medicament (a) comprises said first component and said second component in a weight ratio of from 1:9 to 9:1.

4. A combination product as claimed in claim 3, in which the proportion by weight of said first component exceeds that of said second component.

5. A combination product as claimed in claim 4, in which said first component and said second component are present in a weight ratio of from 6:4 to 8:2.

6. A combination product as claimed in any one of claims 1 to 5, in which the medicament (a) comprises a phosphatidyl glycerol.

7. A combination product as claimed in claim 6, in which the phosphatidyl glycerol comprises one or more diacyl phosphatidyl glycerols, of which at least a proportion of the acyl groups are unsaturated.

8. A combination product as claimed in any one of claims 1 to 7, in which the medicament (a) comprises one or more compounds selected from the group consisting of diacyl phosphatidyl cholines.

9. A combination product as claimed in claim 8, in which the medicament (a) comprises dipalmitoyl phosphatidyl choline.

10. A combination product as claimed in any one of claims 1 to 9, in which the medicament (a) in micronised form.

11. A combination product as claimed in any one of claims 2 to 10, in which said medicament (a) has a median particle size not exceeding 10μm.

12. A combination product as claimed in claim 11, in which said medicament (a) has a median particle size not exceeding 5μm.

13. A combination product as claimed in claim 12, in which said medicament (a) has a median particle size of less than 3μm.

14. A combination product as claimed in any one of claims 1 to 13, in which the antiasthma drug comprises one or more respiratory drugs selected from the group consisting of $ß_2$-agonists, steroids, cromones, antimuscarinic drugs and leukotriene receptor antagonists.

15. A combination product as claimed in any one of claims 1 to 14, which comprises one or more said antiasthma drugs in an amount of up to 10 parts by weight per hundred parts by weight of said first and second components of medicament (a) in combination.

16. A delivery device as claimed in claim 15, which comprises one or more said respiratory drugs in an amount of up to one part by weight per hundred parts by weight of said

first and second components of medicament (a) in combination.

17. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a $ß_2$-agonist.

18. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a steroid.

19. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a cromone.

20. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a leukotriene receptor antagonist.

21. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises an antimuscarinic drug.

22. A combination product as claimed in any one of claims 1 to 21, in which at least ingredient (a) is arranged to be delivered to a patient in the form of at least one individual inhalable dose, the or each individual dose comprising said ingredient (a) in an amount of at least 10mg.

23. A combination product as claimed in claim 22, in which the or each individual dose comprises said first and second components in a combined amount of at least 25mg.

24. A combination product as claimed in claim 23, in which the or each dose comprises said ingredient (a) in a combined amount of at least 40mg.

25. A combination product as claimed in any one of claims 22 to 24, in which at least ingredient (a) is arranged for sequential delivery of a multiplicity of inhalable doses.

26. A combination product as claimed in any one of claims 1 to 25, in which the antiasthma drug is arranged for delivery in admixture with ingredient (a).

27. A combination product as claimed in any one of claims 1 to 26, in which the antiasthma drug is arranged for delivery separately from, and simultaneously or sequentially with, ingredient (a).

28. A pack for use as part of a combination product according to any one of claims 1 to 27, said pack including a delivery device for delivery of ingredient (a) to a patient and further comprising instructions to use said delivery device in a method of treatment including the separate simultaneous or sequential administration of an antiasthma drug.

29. A method of prevention and/or treatment of asthma, comprising administering to a patient at least one dose of a combination product as defined in any one of claims 1 to 27.

30. A delivery device for administering to a patient by inhalation a medicament for the prevention and/or treatment of asthma, the delivery device containing a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL including a component which enhances the spreading of the medicament, the delivery device being arranged for delivery of at least one individual dose in an amount of at least 10mg.

31. A delivery device for administering to a patient by inhalation a medicament for the prevention or treatment of asthma, the delivery device containing a medicament comprising a first component consisting of one or more phosphatidyl cholines and a second component consisting of one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl

palmitate, the delivery device being arranged for delivery of at least one individual inhalable dose, the or each individual dose comprising said first component and said second component in a combined amount of at least 10mg.

32. A delivery device as claimed in claim 30 or claim 31, in which the medicament is as defined in any one of claims 2 to 13.

33. A delivery device as claimed in any one of claims 30 to 32, which further includes means for dispensing an inhalable dose of an antiasthma drug.

34. Use of (a) a surface active phospholipid (SAPL) composition in finely divided form conjointly with (b) an antiasthma drug in the manufacture of a medicament for the control of asthma.

35. A combination product for use in the prevention or treatment of asthma comprising

(a) a medicament comprising a first phospholipid component which is capable of binding to lung tissue and a second component which is capable of enhancing the spreading of said first component over an aqueous medium at 37°C, said medicament being in the form of a finely divided powder; and

(b) an antiasthma drug;

the ingredients (a) and (b) being arranged for administration in combination or separately, simultaneously or sequentially.

INTERNATI L SEARCH REPORT

Int. Application No
PCT/GB 99/03952

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/66 A61P11/06 A61K45/06 //(A61K31/66,31:66,31:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 27920 A (HILLS BRIAN ANDREW ;WOODCOCK DEREK ALAN (GB); BRITANNIA PHARMACEUT) 10 June 1999 (1999-06-10) * see the whole document; in particular claims and the paragraph bridging pages 7 & 8 *	1-15,17, 18,26-35
X	WO 96 22764 A (CIBA GEIGY AG ;TAYLOR PETER WILLIAM (GB); MAAS JANET CATHERINE (GB) 1 August 1996 (1996-08-01) * see in particular claims 1-5,10,11,16, 18,25; Examples 5 & 3 *	1-4,6-8, 10,11, 14,15, 18,26-35

-/—

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 February 2000	03.03.00

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Isert, B

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/03952

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 19199 A (ASTRA AB ;BYSTROEM KATARINA (SE); NILSSON PER GUNNAR (SE)) 27 June 1996 (1996-06-27) * see in particular example 1; claims 1-3, 8-10,16-23, 42-44 *	1,2, 6-12,14, 15,17, 18,20, 22,25-35
X	WO 91 16882 A (LIPOSOME TECHNOLOGY INC) 14 November 1991 (1991-11-14) * see in particular examples 1 & 3 *	1,2,6, 10,11, 14,17, 22,26-35
A	EP 0 528 034 A (TOKYO TANABE CO) 24 February 1993 (1993-02-24) cited in the application *see in particular page 7, lines 4-24; Figures 7-9; page 3, lines 32-53;claims *	1-35

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 99/03952

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 29 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 99/03952

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9927920	A	10-06-1999	AU	1251999 A	16-06-1999
			GB	2331925 A	09-06-1999
WO 9622764	A	01-08-1996	AU	4396196 A	14-08-1996
			CA	2210482 A	01-08-1996
			CN	1169115 A	31-12-1997
			CZ	9702342 A	15-10-1997
			EP	0859598 A	26-08-1998
			FI	973049 A	18-07-1997
			JP	10512876 T	08-12-1998
			NO	973401 A	23-07-1997
WO 9619199	A	27-06-1996	AU	693632 B	02-07-1998
			AU	4360596 A	10-07-1996
			BR	9510512 A	07-07-1998
			CA	2208517 A	27-06-1996
			CN	1171047 A	21-01-1998
			CZ	9701948 A	15-10-1997
			EP	0800383 A	15-10-1997
			FI	972653 A	20-08-1997
			HU	77628 A	29-06-1998
			JP	10510830 T	20-10-1998
			NO	972847 A	19-06-1997
			NZ	298180 A	28-01-1999
			PL	320825 A	10-11-1997
			SK	81497 A	05-11-1997
			TR	970132 A	21-03-1997
			ZA	9510751 A	24-06-1996
WO 9116882	A	14-11-1991	AU	7908791 A	27-11-1991
			CA	2081474 A	09-11-1991
			EP	0527940 A	24-02-1993
EP 0528034	A	24-02-1993	AT	179073 T	15-05-1999
			AU	660612 B	06-07-1995
			AU	7857191 A	10-12-1991
			DE	69131163 D	27-05-1999
			DE	69131163 T	23-12-1999
			WO	9117766 A	28-11-1991

INTERNATIONAL SEARCH REPORT

International Application PCT/US 91/03092

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[6]

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl.5 A 61 K 9/14 A 61 K 9/127 A 61 K 9/72

II. FIELDS SEARCHED

Minimum Documentation Searched[7]

Classification System	Classification Symbols
Int.Cl.5	A 61 K

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched[8]

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category °	Citation of Document,[11] with indication, where appropriate, of the relevant passages[12]	Relevant to Claim No.[13]
X	US-A-4 830 858 (PAYNE et al.) 16 May 1989, see the whole document; in particular examples 1,2	1,4
Y		2,3,5-22
Y	EP-A-0 260 241 (AKTIEBOLAGET DRACO) 16 March 1988, see the whole document; in particular page 8, example 17,; claim 15	2,3,5-22
A	WO-A-8 604 233 (RIKER LABORATORIES INC.) 31 July 1986, see page 3, lines 19-25	6

° Special categories of cited documents :[10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
27-08-1991	19. 09. 91
International Searching Authority	**Signature of Authorized Officer**
EUROPEAN PATENT OFFICE	M. PEIS M. Peis

Form PCT/ISA/210 (second sheet) (January 1985)

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9103092
SA 47880

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 13/09/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A- 4830858	16-05-89	None		
EP-A- 0260241	16-03-88	AU-B-	603139	08-11-90
		AU-A-	7913387	07-04-88
		CA-A-	1256798	04-07-89
		EP-A-	0282537	21-09-88
		JP-T-	1500668	09-03-89
		WO-A-	8801862	24-03-88
		ZA-A-	8706641	14-03-88
WO-A- 8604233	31-07-86	AU-B-	577663	29-09-88
		AU-A-	5306486	13-08-86
		CA-A-	1264297	09-01-90
		EP-A,B	0209547	28-01-87
		JP-T-	62501906	30-07-87
		US-A-	4814161	21-03-89

EPO FORM P0479

14

PATENT COOPERATION TREATY

09 MAR 2001

WIPO PCT

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
CAH/4906WO		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB99/03952	26/11/1999	26/11/1998
International Patent Classification (IPC) or national classification and IPC A61K31/66		
Applicant BRITANNIA PHARMACEUTICALS LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☒ Certain documents cited
   - VII ☒ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
19/06/2000	07.03.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Isert, B Telephone No. +49 89 2399 8691

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/03952

I. Basis f the rep rt

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:
Description, pages:

1-25	as originally filed			

Claims, No.:

17-25,32-35	as originally filed			
8-16	as received on	27/12/2000	with letter of	27/12/2000
1-7,26-30	with telefax of	19/02/2001		

Drawings, sheets:

1/2,2/2	as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

   These elements were available or furnished to this Authority in the following language: , which is:

   - ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
   - ☐ the language of publication of the international application (under Rule 48.3(b)).
   - ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   - ☐ contained in the international application in written form.
   - ☐ filed together with the international application in computer readable form.
   - ☐ furnished subsequently to this Authority in written form.
   - ☐ furnished subsequently to this Authority in computer readable form.
   - ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
   - ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

   ☐ the description, pages:

   ☐ the claims, Nos.:

   ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

   (Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:
   see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

   ☐ the entire international application.

   ☒ claims Nos. 29.

because:

   ☒ the said international application, or the said claims Nos. 29 (for industrial applicability) relate to the following subject matter which does not require an international preliminary examination (*specify*):
   see separate sheet

   ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

   ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

   ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

   ☐ the written form has not been furnished or does not comply with the standard.

   ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;

citations and explanati ns supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	5,13,16,19,21,23,24
	No:	Claims	1-4,6-12,14,15,17,18,20,22,25-30,32-35
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-30,32-35
Industrial applicability (IA)	Yes:	Claims	1-28,30,32-35
	No:	Claims	

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

SECTION I

The claims 1-30, 32-35 are presently on file. The amendments made concern claims 1,16 and 30.

SECTION III

Claim 29 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

SECTION V

1). The following documents (D) cited in the International search report are referred to in this communication; the numbering will be adhered to in the rest of the procedure:

D1 = WO-A- 99 27920
D2 = WO-A- 96 22764
D3 = WO-A- 96 19199
D4 = WO-A- 9116882
D5 = EP -A- 528034 (also cited in the application)

Unless indicated otherwise reference is made to the relevant passages emphasized in the search report.

1.1 The intermediate document D1 represents one of the two priority documents of the present application. In D1 combinations of the SAPLs with anti-asthmatic drugs have also been envisaged but are not mandatory.

2). Novelty

The subject-matter of the claims 1-4,6-12,14,15,17,18,20,22,25-35 is not considered novel:

The documents D2, D3 and D4 disclose inhalation powders comprising at least two SAPLs with anti-asthmatic drugs. In particular, the following combination have been described : DMPC + DOPS + anti-asthma steroid (D2); DPPC/DMPC, + DPPG + anti-asthma steroid (D3); PC + PG + albuterol (D4).

The pro-liposome powders of D2-D4 are in finely divided form, and further considered to be surface-active. The liposomes formed upon rehydration may be found not to be surface active. However, the formation of liposomes requires a certain process, specific amount of water etc., in the absence of which the powders are considered to have surface active properties upon rehydration.

Moreover, the fact that the SAPL of the present application is considered an active ingredient ("medicament") is not considered to confer novelty over the compositions of D2-D4 rather using the SAPL as a carrier.

3). Inventive step

The subject-matter of the present claims is not considered inventive:

The present application relates to the treatment of asthma. It has been shown in the working example that the binding of DPPC to bronchial epithelium in the presence of eggPG (1:1) is increased, which may be indicative for an enhanced antiasthmatic effect, see page 3 lines 20-30 of the present application.

Document D5 describes tests examining the effect of various surfactants on allergic bronchoconstriction. The preparation ALEC (DPPC : PG = 7:3) had a weak effect (Figures 7-9) in comparison to Surfactant TA (Phospholipids + Proteins, inter alia) showing significant effects (page 7, lines 17-24).

On the basis of D5 the problem underlying the present application could be the finding of additives enhancing the anti-asthmatic effect of surfactant.
Having regard to the results obtained with ALEC in D5, and to the non-significant effect of DPPC:DPPG (1:1) described in the present application, it is not conceivable that all the combinations covered by the scope of the present claims would solve the problem posed.
Therefore, solely the combination of DPPC with egg-PG (1:1) which apparently had brought about a significant effect in the working example of the present application, could be considered inventive.

4). Industrial applicability

4.1 For the assessment of the present claim 29 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

4.2 The pharmaceutical products and uses according to claims 1-28, 30, 32-35 are considered industrially applicable under Article 33 (4) PCT.

SECTION VI

D1 = WO-A-9927920, publication date 10.06.1999, filing date 26.11.1999, priority dates 03.12.1997 and 24.12.1997

SECTION VII

5). Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1-D4 is not mentioned in the description, nor are these documents identified therein.

SECTION VIII

6). The presence of at least two phospholipids in component a) of the combination appears to be a feature essential to the performance of the present application, which is however not mandatory in claims 1,30,34.

7). The component a) of claims 1 and 35 is defined by the result to be achieved ("enhances spreading of the medicament....") . The definition given in claim 2, eg., should be used instead. Moreover, the functional definition only makes sense in case the medicament a) consisted of two components. See also page 20, first § of the description.

8. A combination product as claimed in any one of claims 1 to 7, in which the medicament (a) comprises one or more compounds selected from the group consisting of diacyl phosphatidyl cholines.

9. A combination product as claimed in claim 8, in which the medicament (a) comprises dipalmitoyl phosphatidyl choline.

10. A combination product as claimed in any one of claims 1 to 9, in which the medicament (a) in micronised form.

11. A combination product as claimed in any one of claims 2 to 10, in which said medicament (a) has a median particle size not exceeding 10μm.

12. A combination product as claimed in claim 11, in which said medicament (a) has a median particle size not exceeding 5μm.

13. A combination product as claimed in claim 12, in which said medicament (a) has a median particle size of less than 3μm.

14. A combination product as claimed in any one of claims 1 to 13, in which the antiasthma drug comprises one or more respiratory drugs selected from the group consisting of $ß_2$-agonists, steroids, cromones, antimuscarinic drugs and leukotriene receptor antagonists.

15. A combination product as claimed in any one of claims 1 to 14, which comprises one or more said antiasthma drugs in an amount of up to 10 parts by weight per hundred parts by weight of said first and second components of medicament (a) in combination.

16. A combination product as claimed in claim 15, which comprises one or more said respiratory drugs in an amount of up to one part by weight per hundred parts by weight of said

Claims

1. A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL composition including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug, wherein ingredients (a) and (b) are provided in a form for administration together or separately.

2. A combination product as claimed in claim 1, in which the ingredient (a) consists of a first component comprising one or more phosphatidyl cholines and a second component comprising one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate.

3. A combination product as claimed in claim 2, in which medicament (a) comprises said first component and said second component in a weight ratio of from 1:9 to 9:1.

4. A combination product as claimed in claim 3, in which the proportion by weight of said first component exceeds that of said second component.

5. A combination product as claimed in claim 4, in which said first component and said second component are present in a weight ratio of from 6:4 to 8:2.

6. A combination product as claimed in any one of claims 1 to 5, in which the medicament (a) comprises a phosphatidyl glycerol.

7. A combination product as claimed in claim 6, in which the phosphatidyl glycerol comprises one or more diacyl phosphatidyl glycerols, of which at least a proportion of the acyl groups are unsaturated.

26. A combination product as claimed in any one of claims 1 to 25, in which the antiasthma drug is arranged for delivery in admixture with ingredient (a).

27. A combination product as claimed in any one of claims 1 to 26, in which the antiasthma drug is arranged for delivery separately from, and simultaneously or sequentially with, ingredient (a).

28. A pack for use as part of a combination product according to any one of claims 1 to 27, said pack including a delivery device for delivery of ingredient (a) to a patient and further comprising instructions to use said delivery device in a method of treatment including the separate simultaneous or sequential administration of an antiasthma drug.

29. A method of prevention and/or treatment of asthma, comprising administering to a patient at least one dose of a combination product as defined in any one of claims 1 to 27.

30. A delivery device for administering to a patient by inhalation a product according to any one of claims 1 to 27, the device being arranged for delivery of at least one individual dose of the SAPL composition in an amount of at least 10mg.

PCT REQUEST CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

0	**For receiving Office use only**	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	**Form - PCT/RO/101 PCT Request**	
0-4-1	Prepared using	PCT-EASY Version 2.90 (updated 15.10.1999)
0-5	**Petition** The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	**Receiving Office (specified by the applicant)**	United Kingdom Patent Office (RO/GB)
0-7	**Applicant's or agent's file reference**	CAH/4906WO
I	**Title of invention**	IMPROVEMENTS IN AND RELATING TO TREATMENT OF RESPIRATORY CONDITIONS
II	**Applicant**	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	BRITANNIA PHARMACEUTICALS LIMITED
II-5	Address:	41/51 Brighton Road Redhill, Surrey RH1 5TS United Kingdom
II-6	State of nationality	GB
II-7	State of residence	GB
II-8	Telephone No.	01737 773741
II-9	Facsimile No.	01737 762672
III-1	**Applicant and/or inventor**	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	HILLS, Brian, Andrew
III-1-5	Address:	44 Bowsprit Parade Cleveland Queensland, New South Wales 4163 Australia
III-1-6	State of nationality	AU
III-1-7	State of residence	AU

PCT REQUEST CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

III-2	**Applicant and/or inventor**	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	WOODCOCK, Derek, Alan
III-2-5	Address:	44 Shrublands Road Berkhampstead, Hertfordshire HP4 3HX United Kingdom
III-2-6	State of nationality	GB
III-2-7	State of residence	GB
III-3	**Applicant and/or inventor**	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	STANIFORTH, John, Nicholas
III-3-5	Address:	High Trees 170 Boomfield Road Bath, Avon BA2 2ST United Kingdom
III-3-6	State of nationality	GB
III-3-7	State of residence	GB
IV-1	**Agent or common representative; or address for correspondence** The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	HUMPHREYS, Ceris, Anne
IV-1-2	Address:	Abel & Imray 20 Red Lion Street London, WC1R 4PQ United Kingdom
IV-1-3	Telephone No.	0171 242 9984
IV-1-4	Facsimile No.	0171 242 9989
IV-1-5	e-mail	ai@patentable.co.uk
IV-2	**Additional agent(s)**	additional agent(s) with same address as first named agent
IV-2-1	Name(s)	DARBY, David, Thomas; COULSON, Antony, John; BARRY, Patrick, James; SENIOR, Janet; BARDO, Julian, Eason; MAIR, Richard, Douglas; LEGG, Cyrus, James, Grahame; CARTER, Caroline, Ann; NETTLETON, John, Victor; LOWTHER, Deborah, Jane; ADAMS, Nicola; PEARSON, James, Ginn

PCT REQUEST

CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

V	**Designation of States**	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW SD SL SZ TZ UG ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AL AM AT AU AZ BA BB BG BR BY CA CH&LI CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
V-5	**Precautionary Designation Statement** In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	**Exclusion(s) from precautionary designations**	NONE
VI-1	**Priority claim of earlier international application**	
VI-1-1	Filing date	26 November 1998 (26.11.1998)
VI-1-2	Number	PCT/GB98/03543
VI-1-3	PCT receiving Office	GB
VI-2	**Priority claim of earlier national application**	
VI-2-1	Filing date	28 May 1999 (28.05.1999)
VI-2-2	Number	9912639.3
VI-2-3	Country	GB

PCT REQUEST CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

VI-3	**Priority document request** The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):	VI-1, VI-2	
VII-1	**International Searching Authority Chosen**	European Patent Office (EPO) (ISA/EP)	
VIII	**Check list**	number of sheets	electronic file(s) attached
VIII-1	Request	4	-
VIII-2	Description	25	-
VIII-3	Claims	5	-
VIII-4	Abstract	1	abstract.txt
VIII-5	Drawings	2	-
VIII-7	TOTAL	37	
	Accompanying items	paper document(s) attached	electronic file(s) attached
VIII-8	Fee calculation sheet	✓	-
VIII-16	PCT-EASY diskette	-	diskette
VIII-18	**Figure of the drawings which should accompany the abstract**	1	
VIII-19	**Language of filing of the international application**	English	
IX-1	**Signature of applicant or agent**		
IX-1-1	Name (LAST, First)	HUMPHREYS, Ceris, Anne	

FOR RECEIVING OFFICE USE ONLY

10-1	**Date of actual receipt of the purported international application**	
10-2	**Drawings:**	
10-2-1	Received	
10-2-2	Not received	
10-3	**Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application**	
10-4	**Date of timely receipt of the required corrections under PCT Article 11(2)**	
10-5	**International Searching Authority**	ISA/EP
10-6	**Transmittal of search copy delayed until search fee is paid**	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	**Date of receipt of the record copy by the International Bureau**	

PCT (ANNEX - FEE CALCULATION SHEET)

CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

(This sheet is not part of and does not count as a sheet of the international application)

0 0-1	**For receiving Office use only** International Application No.				
0-2	Date stamp of the receiving Office				
0-4	**Form - PCT/RO/101 (Annex)** **PCT Fee Calculation Sheet**				
0-4-1	Prepared using	PCT-EASY Version 2.90 (updated 15.10.1999)			
0-9	**Applicant's or agent's file reference**	CAH/4906WO			
2	**Applicant**	BRITANNIA PHARMACEUTICALS LIMITED, et al.			
12	**Calculation of prescribed fees**		fee amount/multiplier	total amounts (GBP)	
12-1	Transmittal fee	T	⇨	55	
12-2	Search fee	S	⇨	638	
12-3	International fee Basic fee (first 30 sheets)	b1	285		
12-4	Remaining sheets		7		
12-5	Additional amount	(X)	6		
12-6	Total additional amount	b2	42		
12-7	b1 + b2 =	B	327		
12-8	Designation fees Number of designations contained in international application		83		
12-9	Number of designation fees payable (maximum 10)		10		
12-10	Amount of designation fee	(X)	65		
12-11	Total designation fees	D	650		
12-12	PCT-EASY fee reduction	R	-88		
12-13	Total International fee (B+D-R)	I	⇨	889	
12-14	Fee for priority document Number of priority documents requested		2		
12-15	Fee per document	(X)	22		
12-16	Total priority document fee	P	⇨	44	
12-17	**TOTAL FEES PAYABLE (T+S+I+P)**		⇨	1,626	
12-19	**Mode of payment**		cheque		
12-20	**Deposit account instructions** The receiving Office:		United Kingdom Patent Office (RO/GB)		
12-20-2	is hereby authorized to charge any deficiency or credit any over-payment in the total fees indicated above to my deposit account		✓		
12-20-3	is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account		✓		

PCT (ANNEX - FEE CALCULATION SHEET) CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

12-21	Deposit account No.	D00001
12-22	Date	26 November 1999 (26.11.1999)
12-23	Name and signature	HUMPHREYS, Ceris, Anne

VALIDATION LOG AND REMARKS

13-2-6	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.

PCT CAH/4906WO

Original (for **SUBMISSION**) - printed on 26.11.1999 12:47:00 PM

PCT-EASY INFORMATION SHEET

(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG

	Contents
Yellow!	The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.

Before submitting the International Application, please carefully verify that:

-the information contained on printed Request form is correct;
-Box IX of the Request form has been signed;
-all elements of the international application as indicated in Box VIII of the Request form have been attached; and,
-the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The attached PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must copy the submitted application as a template and make the change or correction in a new application (using the submitted application as a template). You may create such a template by copying the submitted application from the "Stored Forms" folder to the "New PCT Forms" folder. Open the new (.0WO) file created in the "New PCT Forms" folder, correct the errors and proceed with the submission process again.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
CAH/4906WO		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/GB 99/03952	26/11/1999	26/11/1998
Applicant		
BRITANNIA PHARMACEUTICALS LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [ ] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [ ] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established by this Authority to read as follows:

   ANTI-ASTHMATIC COMBINATIONS COMPRISING SURFACE ACTIVE PHOSPHOLIPIDS

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [X] None of the figures.

INTERNATIONAL SEARCH REPORT

[redacted]ational application No.
PCT/GB 99/03952

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 29 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
GB 99/03952

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/66 A61P11/06 A61K45/06 //(A61K31/66,31:66,31:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 27920 A (HILLS BRIAN ANDREW ;WOODCOCK DEREK ALAN (GB); BRITANNIA PHARMACEUT) 10 June 1999 (1999-06-10) * see the whole document; in particular claims and the paragraph bridging pages 7 & 8 *	1-15,17, 18,26-35
X	WO 96 22764 A (CIBA GEIGY AG ;TAYLOR PETER WILLIAM (GB); MAAS JANET CATHERINE (GB)) 1 August 1996 (1996-08-01) * see in particular claims 1-5,10,11,16, 18,25; Examples 5 & 3 *	1-4,6-8, 10,11, 14,15, 18,26-35

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 February 2000	03. 03. 00

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Isert, B

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
[redacted]GB 99/03952

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 19199 A (ASTRA AB ;BYSTROEM KATARINA (SE); NILSSON PER GUNNAR (SE)) 27 June 1996 (1996-06-27) * see in particular example 1; claims 1-3, 8-10,16-23, 42-44 *	1,2, 6-12,14, 15,17, 18,20, 22,25-35
X	WO 91 16882 A (LIPOSOME TECHNOLOGY INC) 14 November 1991 (1991-11-14) * see in particular examples 1 & 3 *	1,2,6, 10,11, 14,17, 22,26-35
A	EP 0 528 034 A (TOKYO TANABE CO) 24 February 1993 (1993-02-24) cited in the application *see in particular page 7, lines 4-24; Figures 7-9; page 3, lines 32-53;claims *	1-35

2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 99/03952

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9927920	A	10-06-1999	AU	1251999 A	16-06-1999
			GB	2331925 A	09-06-1999
WO 9622764	A	01-08-1996	AU	4396196 A	14-08-1996
			CA	2210482 A	01-08-1996
			CN	1169115 A	31-12-1997
			CZ	9702342 A	15-10-1997
			EP	0859598 A	26-08-1998
			FI	973049 A	18-07-1997
			JP	10512876 T	08-12-1998
			NO	973401 A	23-07-1997
WO 9619199	A	27-06-1996	AU	693632 B	02-07-1998
			AU	4360596 A	10-07-1996
			BR	9510512 A	07-07-1998
			CA	2208517 A	27-06-1996
			CN	1171047 A	21-01-1998
			CZ	9701948 A	15-10-1997
			EP	0800383 A	15-10-1997
			FI	972653 A	20-08-1997
			HU	77628 A	29-06-1998
			JP	10510830 T	20-10-1998
			NO	972847 A	19-06-1997
			NZ	298180 A	28-01-1999
			PL	320825 A	10-11-1997
			SK	81497 A	05-11-1997
			TR	970132 A	21-03-1997
			ZA	9510751 A	24-06-1996
WO 9116882	A	14-11-1991	AU	7908791 A	27-11-1991
			CA	2081474 A	09-11-1991
			EP	0527940 A	24-02-1993
EP 0528034	A	24-02-1993	AT	179073 T	15-05-1999
			AU	660612 B	06-07-1995
			AU	7857191 A	10-12-1991
			DE	69131163 D	27-05-1999
			DE	69131163 T	23-12-1999
			WO	9117766 A	28-11-1991